Rigel appoints Alison L. Hannah as Chief Medical Officer; Lisa Rojkjaer departs

Rigel appointed Alison L. Hannah as Executive Vice President and Chief Medical Officer, and Lisa Rojkjaer ceased serving as Executive Vice President and Chief Medical Officer.Original SEC Filing: RIGEL PHARMACEUTICALS INC [ RIGL ] - 8-K - Jul. 01, 2026This is an AI-powered summary. It may contain i…

Rigel appointed Alison L. Hannah as Executive Vice President and Chief Medical Officer, and Lisa Rojkjaer ceased serving as Executive Vice President and Chief Medical Officer.

IndividualAlison L. Hannah, M.D.Lisa Rojkjaer, M.D.

RoleExecutive Vice President and Chief Medical OfficerExecutive Vice President and Chief Medical Officer

Type of ChangeAppointedCessation / Separated

Effective DateJuly 1, 2026June 25, 2026

ReasonNot disclosedSeparated from the Company

Replacement InfoN/ANot disclosed

Background DetailsBoard member since May 2021; consultant since 2000 directing cancer therapy development; former CMO of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc.Not disclosed

Board/Committee Role ChangesResigned from Board effective July 1, 2026Not disclosed

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.